Published in J Neurol Sci on August 27, 2013
Focused Ultrasound and Exosomes to Treat Depression, Anxiety, and Dementias | NCT04202770
Synaptic change in the posterior cingulate gyrus in the progression of Alzheimer's disease. J Alzheimers Dis (2015) 0.93
Hippocampal proton MR spectroscopy as a novel approach in the assessment of radiation injury and the correlation to neurocognitive function impairment: initial experiences. Radiat Oncol (2015) 0.77
Increased GABA concentrations in type 2 diabetes mellitus are related to lower cognitive functioning. Medicine (Baltimore) (2016) 0.76
Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias. Funct Neurol (2017) 0.75
Analysis of metabolic characteristics in a rat model of chronic pancreatitis using high-resolution magic-angle spinning nuclear magnetic resonance spectroscopy. Mol Med Rep (2014) 0.75
Alterations in mitochondrial number and function in Alzheimer's disease fibroblasts. Metab Brain Dis (2015) 0.75
Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images. Front Aging Neurosci (2017) 0.75
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet (2011) 2.00
Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med (2012) 1.99
TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener (2013) 1.83
Middle cerebral artery vasospasm: transcranial color-coded duplex sonography versus conventional nonimaging transcranial Doppler sonography. Crit Care Med (2009) 1.53
Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol (2011) 1.40
[Deep brain stimulation and motor cortex and spinal cord stimulation in the treatment of movement disorders and pain syndromes -- the theoretical baseline and practical guidelines]. Neurol Neurochir Pol (2006) 1.38
[Periprocedural and late complications after percutaneous closure of patent foramen ovale: a single centre experience]. Kardiol Pol (2012) 1.38
Genetic variation of Omi/HtrA2 and Parkinson's disease. Parkinsonism Relat Disord (2008) 1.34
Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol (2007) 1.20
GWAS risk factors in Parkinson's disease: LRRK2 coding variation and genetic interaction with PARK16. Am J Neurodegener Dis (2013) 1.03
Mitochondrial DNA haplogroups and subhaplogroups are associated with Parkinson's disease risk in a Polish PD cohort. J Neural Transm (Vienna) (2008) 0.96
Various patterns of gestes antagonistes in cervical dystonia. Parkinsonism Relat Disord (2007) 0.96
A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiol Aging (2009) 0.95
Polymorphism in semaphorin 5A (Sema5A) gene is not a marker of Parkinson's disease risk. Neurosci Lett (2006) 0.93
The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet Genomics (2008) 0.92
A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J Med Genet (2012) 0.90
Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiol Aging (2013) 0.89
Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. PLoS One (2012) 0.88
From mild cognitive impairment to Alzheimer's disease - influence of homocysteine, vitamin B12 and folate on cognition over time: results from one-year follow-up. Neurol Neurochir Pol (2009) 0.88
Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol (2007) 0.87
Analysis of LRRK 2 G 2019 S and I 2020 T mutations in Parkinson's disease. Neurosci Lett (2005) 0.86
Human leukocyte antigen variation and Parkinson's disease. Parkinsonism Relat Disord (2011) 0.85
Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinson's disease in a Polish population. Eur Neurol (2005) 0.85
[Polish forum for prevention guidelines on cardiovascular risk assessment]. Kardiol Pol (2007) 0.84
Cerebral white matter lesions in patients with dementia - from MCI to severe Alzheimer's disease. J Neurol Sci (2009) 0.84
CARD15 variants in patients with sporadic Parkinson's disease. Neurosci Res (2006) 0.83
Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm. Parkinsonism Relat Disord (2007) 0.83
Interleukin-10 gene polymorphism in Parkinson's disease patients. Arch Med Res (2007) 0.82
Mitochondrial transcription factor A variants and the risk of Parkinson's disease. Neurosci Lett (2009) 0.81
Vascular risk factors and intensity of cognitive dysfunction in MCI. J Neurol Sci (2007) 0.81
[Assessment of apolipoprotein E genotype in Parkinson disease patients with and without dementia]. Wiad Lek (2004) 0.79
Phenotype of the DYT1 mutation in the TOR1A gene in a Polish population of patients with dystonia. A preliminary report. Neurol Neurochir Pol (2008) 0.79
Polish Forum for Prevention Guidelines on Arterial Hypertension. Kardiol Pol (2007) 0.79
PARK2 variability in Polish Parkinson's disease patients--interaction with mitochondrial haplogroups. Parkinsonism Relat Disord (2012) 0.79
Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Mov Disord (2013) 0.79
Dopamine beta-hydroxylase -1021C>T association and Parkinson's disease. Parkinsonism Relat Disord (2008) 0.78
Polish forum for prevention guidelines on dyslipidaemia. Kardiol Pol (2008) 0.78
Association of pyridoxal kinase and Parkinson disease. Ann Neurol (2010) 0.78
Polish Forum for Prevention Guidelines on overweight and obesity. Kardiol Pol (2008) 0.77
Polish Forum for Prevention Guidelines on cardiovascular diseases prevention in children and adolescents. Kardiol Pol (2010) 0.77
Decompressive hemicraniectomy in ischaemic stroke. Neurol Neurochir Pol (2010) 0.77
Polish Forum for Prevention Guidelines on physical activity. Kardiol Pol (2009) 0.77
The influence of visual control on postural stability in Parkinson disease. Neurol Neurochir Pol (2011) 0.77
Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. Neurobiol Aging (2011) 0.77
Polish Forum for Prevention Guidelines on Diabetes. Kardiol Pol (2008) 0.76
Polish forum for prevention guidelines on diet. Kardiol Pol (2008) 0.76
Polish forum for prevention guidelines on smoking. Kardiol Pol (2008) 0.76
Corticobasal degeneration -- clinico-pathological considerations. Folia Neuropathol (2006) 0.76
[Inferior frontal region hypoperfusion in Parkinson disease with dementia]. Neurol Neurochir Pol (2003) 0.76
Perfusion computed tomography in prediction of functional outcome in patients with acute ischaemic stroke. Nucl Med Rev Cent East Eur (2009) 0.76
ALS-FTD complex disorder due to C9ORF72 gene mutation: description of first Polish family. Eur Neurol (2014) 0.75
[Parkinsonism in chronic occupational metallic mercury intoxication]. Neurol Neurochir Pol (2003) 0.75
[Stereotactic pallidotomy and thalamotomy in the treatment of primary dystonia]. Neurol Neurochir Pol (2007) 0.75
Polish forum for prevention guidelines on psychosocial cardiovascular disease risk factors. Kardiol Pol (2009) 0.75
Percutaneous closure of the left atrial appendage to prevent ischaemic stroke in patients with atrial fibrillation who require but have contraindications to oral anticoagulation. Neurol Neurochir Pol (2012) 0.75
[Clinical classification of tremor]. Wiad Lek (2002) 0.75
[Teleneurology: a new form of physician--patient communication]. Wiad Lek (2005) 0.75
[Report from the 2nd Congress of the Section of Extrapyramidal Disorders of the Polish Neurological Society, Szczryrk, May 8-10, 2003]. Neurol Neurochir Pol (2004) 0.75
[Functional imaging in movement disorders]. Neurol Neurochir Pol (2006) 0.75
Polish Forum for Prevention of Cardiovascular Diseases Guidelines on prophylactic pharmacotherapy. Kardiol Pol (2011) 0.75
Acute intracranial in-stent thrombosis after angioplasty of middle cerebral artery symptomatic stenosis: a case report. Neurologist (2012) 0.75
[Consensus regarding indications for surgical treatment of Parkinson disease]. Neurol Neurochir Pol (2003) 0.75
[85-years-old patient with paraneoplastic polyneuropathy]. Wiad Lek (2007) 0.75
An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting. Med Sci Monit (2002) 0.75
Polish Forum for Prevention Guidelines for screening procedures for cardiovascular diseases. Kardiol Pol (2011) 0.75
Polish forum for prevention guidelines on metabolic syndrome. Kardiol Pol (2010) 0.75
[Changes in central nervous system during preeclampsia]. Wiad Lek (2005) 0.75
Polish forum for prevention guidelines on cardiovascular diseases prevention in women. Kardiol Pol (2007) 0.75
[Dopamine agonists in the future--clinical trials of new medications]. Neurol Neurochir Pol (2007) 0.75
[The role of environmental factors in Parkinson's disease may depend on disease onset age]. Neurol Neurochir Pol (2005) 0.75
Polish Forum for Prevention Guidelines on the so-called new cardiovascular risk factors and markers, which have a potentially significant role in the strategy for the prevention of cardiovascular diseases. Kardiol Pol (2007) 0.75
[Sleep disturbances in Parkinson's disease]. Neurol Neurochir Pol (2005) 0.75